美國Xencor www.xencor.com
美國Xencor公司2006年3月宣布，通過使用專有的“XmAb”技術在單克隆抗體的穩(wěn)定區(qū)（Fc）導入變異，增強Fc受體的親和性及特異性，因此把對靶細胞的抗體依賴性細胞毒性（ADCC）的活性成功地在in vitro實驗提高到100倍、在in vivo實驗提高到10倍以上。研究得到的結果有望增強已經確定了靶細胞的癌癥的治療效果。

Xencor has built one of the most powerful protein engineering technology platforms in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb® antibody therapeutics and XPro™ protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we generate entirely new therapeutic mechanisms of action.
In collaboration with our partners—including leading pharmaceutical companies Boehringer Ingelheim, Centocor, and Pfizer—we are selectively designing next-generation protein drug candidates with superior pharmacological properties and novel molecular compositions. Our internal pipeline of next-generation antibodies and protein therapeutics for cancer, inflammation and autoimmune disease address well understood and validated targets with improved selectivity, efficacy, safety and dosing convenience.